Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

51.32 -2.23 (-4.16%)
Streaming Delayed Price Updated: 1:32 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Analyzing CRISPR Therapeutics's Unusual Options Activity
Shares of CRISPR Therapeutics (NASDAQ:CRSP) saw some unus... 
Via Benzinga
Why CRISPR Therapeutics Stock Fell 25.2% in July
The stock dropped roughly $40 per share over the course of the month. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
Better Buy: Vertex vs. CRISPR
Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run. 
Via The Motley Fool
CRSP Stock: The Good News Goosing CRISPR Therapeutics Shares Today
Shares of CRSP stock are rising on Friday after CRISPR Therapeutics provided a positive business update regarding its leading drug candidate. 
Via InvestorPlace
Why CRISPR Therapeutics' Stock Is Trading Higher Today
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading higher Friday morning after the company announced second-quarter financial results that showed significant improvement year over... 
Via Benzinga
Why CRISPR Therapeutics' Stock Is Trading Higher Today
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year. 'We expect... 
Via Benzinga
Crispr Therapeutics Represents the Best of Emerging Biotechnology
CRSP stock may end up being a pioneer, or it may fizzle. The timeline until we know is typical of biotech stocks. 
Via InvestorPlace
Is CRISPR Therapeutics a Millionaire-Maker Stock?
It's already well on its way, but the road ahead will be long. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
3 Things About CRISPR Therapeutics That Smart Investors Know
The company is on track to be the first to market with a gene-editing therapy for blood disorders. 
Via The Motley Fool
Crispr Therapeutics Has Bullish DNA
Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning. 
Via InvestorPlace
Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Concerns?
Ethical concerns will likely dog CRISPR Therapeutics stock, especially with the present social awakening. 
Via InvestorPlace
Topics Economy
Exposures COVID-19 Economy
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
Cramer Gives His Opinion On Wynn Resorts, Advanced Micro Devices And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Group Inc (NYSE: BX) very much. He keeps buying Wynn Resorts, Limited (NASDAQ: WYNN) for... 
Via Benzinga
How Investors Can Own A Piece Of Tesla, Shopify, CRISPR Therapeutics
Investing in the ARK Innovation ETF (NYSE:ARKK) is the ... 
Via Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
There are still some key unanswered questions for the biotech's promising gene-editing therapy. 
Via The Motley Fool
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
Exposures Fossil Fuels Securities Market US Equities
Here's What Drove Gene Editing Stocks Higher This Week
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers. 
Via The Motley Fool
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns... 
Via Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. 
Via InvestorPlace
Why Gene Editing Stocks Are Trading Higher Again Today
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high. 
Via Investor's Business Daily
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. 
Via InvestorPlace
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
Crispr Therapeutics Stock Sees Improved Relative Strength Rating
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74. 
Via Investor's Business Daily
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.